GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » Land And Improvements

Vectus Biosystems (ASX:VBS) Land And Improvements : A$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Vectus Biosystems Land And Improvements?

Vectus Biosystems's land and improvements for the quarter that ended in Dec. 2024 was A$0.00 Mil.


Vectus Biosystems Land And Improvements Historical Data

The historical data trend for Vectus Biosystems's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Land And Improvements Chart

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Land And Improvements
Get a 7-Day Free Trial Premium Member Only - - - - -

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Land And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Vectus Biosystems Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.


Vectus Biosystems Business Description

Traded in Other Exchanges
N/A
Address
26-34 Dunning Avenue, Unit 5, Ground Floor, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. It operates in one segment, being pharmaceutical research and development.

Vectus Biosystems Headlines

No Headlines